🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise around the world, with estimates suggesting over 82 million instances each year. Notably increased rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This infection can lead to major issues, including infertility. Experts believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Outcomes and Global Access

Based on results released by a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which combines an injection and a pill. The trial enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have shared optimism. Having a one-pill regimen like this is hailed as a "revolutionary step" for public health efforts. This is considered crucial to alleviate the strain of the disease for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.